Effects of metronidazole on midazolam metabolism in vitro and in vivo

European Journal of Clinical Pharmacology

Volumn 56, Issue 8, 2000, Pages 555-559

  Wang, J S ^a   Backman, J T ^a   Kivisto K T ^a   Neuvonen, P J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cytochrome P450 3A4; Metronidazole; Midazolam

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYCLOSPORIN; CYTOCHROME P450 3A4; METRONIDAZOLE; MIDAZOLAM; MIDAZOLAM MALEATE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; METRONIDAZOLE; MICROSOMES, LIVER; MIDAZOLAM; MIXED FUNCTION OXYGENASES; PSYCHOMOTOR PERFORMANCE;

EID: 0033661877     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000201     Document Type: Article

References (29)

1. The stereoselective interaction of warfarin and metronidazole in man
2. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam
3. Cytochrome P450 isozymes and antiepileptic drug interactions
4. Cyclosporine interactions with metronidazole and cimetidine
5. Possible pharmacokinetic interaction with quinidine: Ciprofloxacin or metronidazole?
6. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update
7. Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy
8. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers
9. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
10. Excretion and metabolism of 14C-midazolam in humans following oral dosing
11. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
12. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
13. Midazolam is metabolized by at least three different cytochrome P450 enzymes
14. Midazolam metabolism by modified Caco-2 monolayers: Effects of extracellular protein binding
15. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
16. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
17. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation
18. Noninvasive tests of CYP3A enzymes
19. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation
20. Protein measurement with the folin phenol reagent
21. Midazolam alpha-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole
22. Determination of midazolam and its alpha-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography
23. A rapid and specific semi-micro method involving high-pressure liquid chromatography for the assay of metronidazole in plasma, saliva, serum, urine and whole blood
24. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
25. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam
26. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily
27. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture
28. Human P-glycoprotein transports cyclosporin A and FK506
29. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice